Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422376 · ClinicalTrials.gov registry record · NA
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
A NA study of Alopecia, sponsored by Charles Mays.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07422376: Recruiting NA study of Alopecia, sponsored by Charles Mays.
NCT07422376 is a NA study of Alopecia that is actively recruiting participants, run by Charles Mays. The registered enrollment target is 100 participants, below the 117-participant average among 13 other Alopecia trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07422376, a NA study of Alopecia, is actively recruiting participants, sponsored by Charles Mays.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-blind, randomized controlled trial is proposed to assess the effects of the PAXMAN Scalp Cooling System on the quality of life of breast cancer subjects receiving any treatment regimen consisting of a chemotherapy agent known to cause chemotherapy-induced alopecia (CIA). Quality of life will be measured using the Chemotherapy-Induced Alopecia Distress Scale (CADS) for cancer patients pre-and post-treatment. Simultaneously, the effect of scalp cooling on hair retention and regrowth will be determined by self-reported grading of photographic assessment using the Alopecia (Hair Loss) Pictorial Tool. Results will be correlated with presence of single nucleotide variations (SNVs) rs3820706 in the CACNB4 gene and rs1202179 in the ABCB1 gene. Participants will be blinded to genetic results until the completion of the study to prevent bias, as knowing results could influence the participants' behavior.
Primary Outcome
To determine whether the PAXMAN Scalp Cooling System is effective for improving the quality of life of breast cancer subjects in the Appalachian Highlands region. The Self-Reported Alopecia (Hair Loss) Pictorial Tool will be performed to specifically evaluate hair retention and regrowth (on Day 1 and post-treatment 4 weeks (± 1 week), 8 weeks (± 1 week), and 12 weeks (± 1 week)). Grading will be for 0 to 2, with 0 being No Significant Hair Loss, 1 being Hair Loss up to 50%, and 2 being Hair Loss
Conditions Studied
Interventions
- DEVICE Paxman Scalp Cooling System
Study Locations (1)
Tennessee
- Ballad Health Cancer Care - Kingsport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT07422376 shows while recruiting
NCT07422376 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 117-participant average among 13 other Alopecia trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Paxman Scalp Cooling System is the first listed.
NCT07422376 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07422376 about?
NCT07422376 is a clinical study titled "Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region". This single-blind, randomized controlled trial is proposed to assess the effects of the PAXMAN Scalp Cooling System on the quality of life of breast cancer subjects receiving any treatment regimen consisting of a chemotherapy agent known to cause chemotherapy-induced alopecia (CIA). Quality of life ...
What is the current status of trial NCT07422376?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-03-01. Estimated completion is 2027-01-01.
What conditions does trial NCT07422376 study?
This clinical trial studies the following conditions: Alopecia.
What interventions are being tested in trial NCT07422376?
The interventions under investigation include: Paxman Scalp Cooling System (DEVICE).
Who is sponsoring clinical trial NCT07422376?
This trial is sponsored by Charles Mays, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422376 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07422376's enrollment target sits among peer trials
100 4th of 13 higher than 10 of 13 other Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
RECRUITING · NA
-
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI